Artificial Intelligence
April 23–25, 2018
Boston, MA • United States

Paul Ridker, MD

  • Director, Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital
  • Eugene Braunwald Professor of Medicine, Harvard Medical School

Dr. Ridker serves as the Eugene Braunwald Professor of Medicine at the Harvard Medical School and directs the Center for Cardiovascular Disease Prevention, a translational epidemiologic research unit at the Brigham and Women’s Hospital in Boston focused on population biology, genetic epidemiology, and the biology of innate immunity and vascular inflammation as it relates to cardiovascular disease and atherosclerosis. Among many ongoing multi-national projects, Dr. Ridker currently serves as Trial Chairman of the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) and the NIH-sponsored Cardiovascular Inflammation Reduction Trial (CIRT), two large-scale outcome trials seeking to address whether reducing inflammation without altering LDL cholesterol can reduce vascular event rates. The recipient of numerous awards and honorary degrees, Dr. Ridker has had continuous investigator initiated RO1 grant support from the NIH throughout his career and, with Professor Julie Buring, direct a T32 training program in Cardiovascular Epidemiology which is in its 26th year.

This speaker appears at this event: